Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Approved
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
1 competitor in hATTR Amyloidosis
View Full LandscapeTarget Indication
hATTR Amyloidosis
Mechanism of Action
RNAi Therapeutic
Clinical Trial
NCT03759379Last updated: 12/3/2025
Latest Patent Expiry
Patents Listed
13
Exclusivity
Application
NDA 215515Amvuttra
Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.